Development and Validation of a Discriminating In Vitro Dissolution Method for Oral Formulations Containing Satranidazole

Table 10

Dissolution of marketed tablet.

Time (minutes)	% cumulative release
0	0
5	9.34 ± 0.432
10	28.87 ± 0.471
15	39.1 ± 0.572
30	65.43 ± 0.503
45	83.66 ± 0.66
60	88.1 ± 0.55